Smoking Claims 1.35 Million Indian Lives Each Year: Experts Call for Science-Backed Alternatives in Fight Against Tobacco

Spread the Message

Read Time:4 Minute, 39 Second

Tobacco’s Heavy Toll

India faces a severe tobacco epidemic, with a staggering 1.35 million deaths each year attributed to smoking and related illnesses. Despite decades of public health campaigns and policy interventions, quit rates remain worryingly low—just 7% of Indian smokers successfully quit unaided, according to latest figures from the Centers for Disease Control and Prevention (CDC). This health crisis, predominantly affecting adults across India, continues to burden families and the nation’s healthcare system, costing more than Rs 1.77 lakh crore (INR 1773.4 billion) annually, about 1% of India’s GDP. As awareness grows, healthcare leaders and researchers are urging for innovative, evidence-based harm reduction strategies, including stricter tobacco control policies and consideration of safer nicotine alternatives.

The Scale of Tobacco-Related Illness in India

Death and Disease: Every tenth death in India is linked to tobacco. Both smoked and smokeless forms are responsible for life-threatening conditions like cardiovascular disease, chronic obstructive pulmonary disease (COPD), cancer, and stroke.
Economic Impact: The direct and indirect costs of treating tobacco-related illnesses exceed US $27.5 billion annually. Medical expenses account for 22% of this burden, while lost productivity and premature death contribute 78%.
Population Affected: India is home to nearly 267 million tobacco users, making it one of the world’s top tobacco-consuming nations.

Quit Rates and Barriers to Cessation

Despite widespread awareness of the risks, quit rates are low. National data indicate only 7% succeed without medical assistance, while community quitline services show abstinence rates of up to 38.5% among dedicated participants. Factors affecting cessation include:

Socioeconomic Disparities: Access to quit support and cessation medications can be uneven.
Cultural Norms: Deep-rooted social acceptance of tobacco in certain regions creates additional barriers.
Limited Success of Traditional Treatments: Nicotine replacement therapies and behavioral programs have shown only moderate success.

New Frontiers: Smoke-Free Nicotine Alternatives

Experts are exploring smoke-free nicotine products, such as nicotine pouches and electronic devices, as potential harm reduction tools. Dr. Pawan Gupta, senior consultant at BLK-MAX Super Specialty Hospital, Delhi, emphasizes, “For patients with COPD or cardiovascular risks, every cigarette avoided matters. Scientific reviews—including those by the Royal College of Physicians (UK)—show that non-combustible nicotine delivery carries significantly lower risks compared to smoking. That evidence cannot be ignored”.

Evidence from Public Health England suggests that these alternatives are up to 95% less harmful than conventional cigarettes, primarily because they eliminate tar and combustion—the main sources of cancer-causing agents. However, experts caution that these products are not risk-free.

Dr. Sunaina Soni, Assistant Professor, Department of Physiology, AIIMS-CAPFIMS Centre, notes, “Traditional cessation tools often have limited success in India. Safer, tobacco-free nicotine alternatives, when strictly regulated, could support smokers in moving away from cigarettes. No smoke, no tar, no combustion; that is the critical difference. Science speaks, and it’s time we consider safer nicotine”.

Recent Studies and Global Trends

Effectiveness of Nicotine Pouches: Recent studies in Saudi Arabia and the U.S. show 41% of nicotine pouch users report success in quitting smoking, while preliminary trials suggest higher nicotine strengths may facilitate greater reductions in cigarette use. Adverse effects are generally mild, with nausea and headaches being the most common.
Global Availability: Smoke-free nicotine products are accessible in 34 countries, including the U.S., Sweden, Norway, and Denmark.
Regulatory Landscape: In India, nicotine pouches are not yet fully approved for smoking cessation, and authorities stress the need for further research and strict regulation.

Expert Perspectives: Diverse and Cautious

While some clinicians back harm reduction strategies, others warn against premature optimism. Dr. Anuj Sharma, a pulmonologist not linked to the studies, states, “While harm reduction holds promise, it’s critical that products are regulated, supported by robust evidence, and not marketed to youth. Smoking cessation must remain the primary goal.”

Similarly, the World Health Organization (WHO) prioritizes comprehensive tobacco control strategies—from advertising bans and taxation to community counseling and pharmacological support. These methods have shown progress: WHO statistics indicate India is “on track” to achieve a 30% reduction in tobacco use prevalence by 2025 compared to 2010, largely due to policy interventions.

Implications for Public Health and Daily Life

Harm reduction approaches may offer a pragmatic pathway for millions unable to quit, but they are not a substitute for quitting altogether. Individuals considering alternatives should consult their healthcare provider for personalized advice.
Increased access to quitline services and cessation counseling is crucial for rural and low-income communities, where tobacco use remains highest and health consequences most severe.
For the general public, avoiding smoking and seeking professional support to quit remain the most effective steps for reducing health risks.

Limitations and Counterarguments

Research on long-term safety of nicotine pouches and electronic nicotine delivery systems is ongoing and inconclusive.
Concerns exist that new products may inadvertently attract non-smokers and youth if marketing controls lapse.
Some past studies supporting these products have been funded by the tobacco industry, raising conflict of interest concerns and requiring independent verification.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.